86864-60-0

Usage

Uses

Used in Organic Synthesis:
(2-BROMOETHOXY)-TERT-BUTYLDIMETHYLSILANE is used as a reagent for the selective N-alkylation of 5-piperazin-1-yl-1H-indole and (1H-indol-2-yl)-piperazin-1-yl-methanone. It facilitates the synthesis of 4-(3-hydroxypropyl)-4′-methyl-2,2′-bipyridine and 2-[3-[(3,4,5-trimethoxyphenyl)thio]-1H-indol-5-yloxy]ethanol, which are important intermediates in the development of pharmaceutical compounds.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, (2-BROMOETHOXY)-TERT-BUTYLDIMETHYLSILANE is used as a reagent for the synthesis of various drug candidates. Its ability to selectively N-alkylate certain compounds makes it a valuable tool in the development of new medications with improved efficacy and reduced side effects.
Used in Chemical Research:
(2-BROMOETHOXY)-TERT-BUTYLDIMETHYLSILANE is also utilized in chemical research for studying the reactivity and properties of different organic molecules. Its unique structure allows researchers to explore new reaction pathways and develop innovative synthetic methods for the preparation of complex organic compounds.

InChI:InChI=1/C8H19BrOSi/c1-8(2,3)11(4,5)10-7-6-9/h6-7H2,1-5H3

Upstream product

• 18162-48-6 tert-butyldimethylsilyl chloride 
• 540-51-2 2-bromoethanol 
• 288-32-4 1H-imidazole 
• 102229-10-7 2-(tert-butyldimethylsilyloxy)ethanol 

Downstream Products

• 86864-31-5 5-<(tert-Butyldimethylsilyl)oxy>-2-pentanone Tritylsulfenimine 
• 86864-43-9 N-[2-(tert-Butyl-dimethyl-silanyloxy)-ethyl]-N-isopropenyl-S-trityl-thiohydroxylamine 
• 189251-22-7 N-[2-(tert-Butyl-dimethyl-silanyloxy)-ethyl]-4-methyl-N-(1-propyl-hept-6-enyl)-benzenesulfonamide 
• 189251-21-6 N-[2-(tert-Butyl-dimethyl-silanyloxy)-ethyl]-4-methyl-N-((R)-1-propyl-hept-6-enyl)-benzenesulfonamide 
• 189251-20-5 (7S)-7-({2-[(tert-butyl)dimethylsilyloxy]ethyl}(p-tolylsulfonyl)amino)dec-1-ene 
• 259738-70-0 2-tert-butoxycarbonylamino-3-{4-[2-(tert-butyl-dimethyl-silanyloxy)-ethoxy]-phenyl}-propionic acid 2-(tert-butyl-dimethyl-silanyloxy)-ethyl ester 
• 133305-43-8 [2-(4-Bromophenoxy)ethoxy](1,1-dimethylethyl)dimethylsilane 
• 329309-29-7 N-[2-(tert-butyldimethylsilyloxy)ethyl]-N-(2-methylhept-6-en-2-yl)-p-toluenesulfonylamide 
• 465545-20-4 (4S,6R)-4-cyano-4-(2-(tert-butyldimethylsilyloxy)-ethyl)-6-(2-phenylethyl)-2,2-dimethyl-1,3-dioxane 
• 304015-28-9 methyl 2-(2-{[tert-butyl(dimethyl)silyl]oxy}ethoxy)-4-nitrobenzoate 
• 873577-53-8 1-[2-(tert-butyl-dimethyl-silanyloxy)-ethyl]-5-(4-chloro-phenyl)-pyrrolidin-2-one 

Relevant academic research and scientific papers

Copper-Catalyzed Reaction of C60 with Tertiary Amines for the Preparation of Spiro-Linked Methanofullerenes and Fullerenoalkanals

CuI-catalyzed reaction of C60 with tertiary amines by using air as the sole oxidant has been developed. Spiro-linked methanofullerenes bearing cyclic amides and fullerenoalkanals can be obtained selectively using the cyclic and acyclic amines a

Distance of hydroxyl functionality from the quaternized center influence DNA binding and in vitro gene delivery efficacies of cationic lipids with hydroxyalkyl headgroups

In vitro gene delivery efficacies of cationic amphiphiles 1-7 (Scheme 1) were measured by both the reporter gene expression assays in CHO, COS-1, HepG2, and MCF7 cells and by the whole cell histochemical X-gal staining of representative Chinese hamster ovary cells. Our results demonstrated that in vitro gene delivery efficiencies of cationic lipids with hydroxyalkyl headgroups are adversely affected by increased covalent distances between the hydroxyl functionality and the cationic centers. Findings in the DNase I protection experiments and transmission electron microscopic study support the notion that such compromised gene delivery efficacies may originate from poor lipid - DNA binding interactions and significantly increased lipoplex nanosizes.

Acid-Catalyzed Intramolecular Ring-Opening Reactions of Cyclopropanated Oxabenzonorbornadienes with Carboxylic Acid Nucleophiles

The present work demonstrates the ability of carboxylic acid tethered cyclopropanated oxabenzonorbornadienes (CPOBDs) to undergo ring-opening reactions in mild acidic conditions. The optimized reaction conditions involve the use of pTsOH in DCE at 90 °C. Two regioisomers are formed but the reactions are highly regioselective towards type 3 ring-opened products. It was observed that substitution at the C5 and aryl positions of CPOBD significantly hinders the ring-opening reactions leading to decreased yields of ring-opened products, although high regioselectivity for the Type 3 ring-opened products is still maintained. Herein, the first examples of acid-catalyzed intramolecular ring-opening reactions of CPOBD with carboxylic acid nucleophiles are reported.

Degradable resin monomer synthesized from dicyclohexylketone and preparation method of degradable resin monomer

The invention belongs to a degradable photoresist resin monomer, and discloses a degradable resin monomer synthesized from dicyclohexylketone and a preparation method of the degradable resin monomer.The structural formula of the resin monomer is shown in

Degradable resin monomer synthesized from 2 -cyclopentyl cyclopentanone and preparation method and application thereof

The invention relates to the technical field of photoresist and discloses a degradable resin monomer synthesized from 2 - cyclopentylcyclopentanone and a preparation method and application thereof. Wherein R is an alkyl group or a heteroalkyl group. Under the action of the acid, the tert-butyl structure is broken, so that the edge roughness of the photoresist is improved, the resolution of the photoresist is improved, the dissolution in the developing process is improved, the dissolving speed of the photoresist in the developing solution is increased, and the contrast of the photoresist is increased.

SMALL MOLECULE VE-PTP INHIBITORS

The present disclosure relates to compounds capable of inhibiting vascular endothelial protein tyrosine phosphatase (VE-PTP). These compounds are also capable of activating Tie2 receptor-mediated signaling. The present disclosure also relates to pharmaceutically acceptable salts of said compounds, to pharmaceutical compositions comprising such compounds and/or pharmaceutically acceptable salts thereof, and to the use of such compounds, pharmaceutically acceptable salts thereof, and/or pharmaceutical compositions comprising the same in treating diseases and/or conditions mediated by VE-PTP signaling, such as those mediated by Angiopoietm/Tie2 signaling.

PYRAZOLOTRIAZOLOPYRIMIDINE DERIVATIVES AS A2A RECEPTOR ANTAGONIST

Disclosed herein is a pyrazolotriazolopyrimidine derivative or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof useful as A2A receptor antagonist, and a pharmaceutical composition comprising the same. Also disclosed herein is a method of treating cancer using the pyrazolotriazolopyrimidine derivative or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof as A2A receptor antagonist.

Multiaction Platinum(IV) Prodrug Containing Thymidylate Synthase Inhibitor and Metabolic Modifier against Triple-Negative Breast Cancer

Multifunctional platinumIV anticancer prodrugs have the potential to enrich the anticancer properties and overcome the clinical problems of drug resistance and side effects of platinumII anticancer agents. Herein, we develop dual and triple action platinumIV complexes with targeted and biological active functionalities. One complex (PFL) that consists of cisplatin, tegafur, and lonidamine exhibits strong cytotoxicity against triple negative breast cancer (TNBC) cells. Cellular uptake and distribution studies reveal that PFL mainly accumulates in mitochondria. As a result, PFL disrupts the mitochondrial ultrastructure and induces significant alterations in the mitochondrial membrane potential, which further leads to an increase in production of reactive oxygen species (ROS) and a decrease in ATP synthesis in MDA-MB-231 TNBCs. Western blot analysis reveals the formation of ternary complex of thymidylate synthase, which shows the intracellular conversion of tegafur into 5-FU after its release from PFL. Furthermore, treatment with PFL impairs the mitochondrial function, leading to the inhibition of glycolysis and mitochondrial respiration and induction of apoptosis through the mitochondrial pathway. The RNA-sequencing experiment shows that PFL can perturb the pathways involved in DNA synthesis, DNA damage, metabolism, and transcriptional activity. These findings demonstrate that PFL intervenes in several cellular processes including DNA damage, thymidylate synthase inhibition, and perturbation of the mitochondrial bioenergetics to kill the cancer cells. The results highlight the significance of a triple-action prodrug for efficient anticancer therapy for TNBCs.

Design, synthesis and biological evaluation of potent EGFR kinase inhibitors against 19D/T790M/C797S mutation

The efficacy of EGFR inhibitors is frequently affected by acquired resistance. EGFR19D/T790M/C797S mutation is one of the primary reasons for the emergence of resistance after treatment with the third-generation EGFR inhibitors such as AZD9291, CO1686 and Olmutinib. To overcome the resistance mutation 19D/T790M/C797S, we designed and prepared a series of indole derivatives with the terminal hydroxyl of alkyl chain to increase extra interaction with the Asp855 in the conservative DFG site. Activity evaluation, structure-activity relationship and docking analysis were also carried out. Among them, compound 12e displayed significant inhibitory activity against EGFR19D/T790M/C797S (IC50 = 15.3 nM) and good selectivity over EGFR WT (IC50 > 1000 nM), L858R/T790M (IC50, 156.6 nM) and L858R/T790M/C797S (IC50, 218.3 nM) respectively. Furthermore, 12e exhibited good growth inhibition activity, induced G1 phase cell cycle arrest and apoptosis in BaF3/EGFR19D/T790M/C797S cells by suppressing EGFR phosphorylation signaling pathway. In all, our study might provide a novel structural design method and lay the solid foundation for the development of the 4th generation EGFR19D/T790M/C797S inhibitors.

PHOSPHONATE CONJUGATES AND USES THEREOF

Phosphonate conjugates, preferably, bisphosphonate conjugates; methods of inhibiting Ron receptor tyrosine kinase and methods of treatment of bone destruction due to cancer or other conditions utilizing the provided phosphonate conjugates.